PharmaLeaders: Top 10 Pharmaceutical Companies in India Benchmark Report – Competitive Analysis of the Leading Players in 2013

0
shares
Be First to Share ->
Share on Twitter
Share on Google+
Share on LinkedIn
Pin to Pinterest
Share on StumbleUpon
+
What's This?

London (PRWEB) November 05, 2013

PharmaLeaders: Top 10 Pharmaceutical Companies in India Benchmark Report – Competitive Analysis of the Leading Players in 2013

Summary

GlobalData’s “PharmaLeaders: Top 10 Pharmaceutical Companies in India Benchmark Report – Competitive Analysis of the Leading Players in 2013” applies GlobalData’s proprietary ranking methodology to compare the competitive position of 10 India-based pharmaceutical companies on 15 financial metrics. The performance of each of these companies is analyzed based on their financial performance, cost-containment, capital structure, and efficiency to illustrate the different strategies these companies are using to increase shareholder value and capture market share from branded pharmaceuticals manufacturers. In addition to the financial metrics, this report presents competitive landscapes of the various markets in which these companies operate, as well as detailed company profiles, including SWOT analyses, of these major players. It also describes the operations strategies of these companies.

Throughout the report, GlobalData’s analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools you need to make informed business decisions.

Highlights

About the Report

This report is an essential source of information and analysis on the Indian pharmaceutical industry. Using detailed company data, financial analysis, corporate strategy, and market trends analysis, GlobalData has highlighted 10 companies in the Indian pharmaceuticals space, forming a basis for in-depth analysis of the current and future growth drivers of the domestic pharmaceuticals market. The report discusses the key factors shaping and driving the Indian pharmaceutical industry, and provides insight on the competitive landscape and emerging strategies that are expected to significantly alter the market position of the industry leaders.

Key Questions Answered

-What are the drivers of the Indian pharmaceutical industry?

-What is the forecast for the Indian pharmaceutical market to 2020?

-What specific strategies are pharmaceutical companies in India employing to capture market share from branded and generic pharmaceutical companies worldwide?

-How are these companies dealing with cost-containment to increase their margin?

-How does my assets utilization and overall manufacturing efficiency match up with theirs?

-How are these pharmaceutical companies maximizing their capital spending to attain a competitive advantage?

Scope

-The report includes a financial model, which uses GlobalData’s proprietary benchmarking methodology to rank 10 leading pharmaceutical companies in India on 15 different financial metrics

-The report provides analysis of the key drivers and trends shaping the Indian pharmaceutical industry

-The report provides a geographic segmentation and competitive assessment of the various markets in which the companies covered in the report market their products.

-The report contains expert insights on the corporate strategies of Indian pharmaceutical companies seeking competitive advantage in the highly competitive generics industry

-The report includes in-depth company profiles of the 10 Indian pharmaceutical companies featured, including insightful SWOT analyses

Key Benefits

-Understand the key factors driving the substantial growth being witnessed in the Indian pharmaceutical industry and the market’s outlook through 2020

-Benchmark your company’s performance against other pharmaceutical companies in India to identify strengths that can be leveraged and/or areas of possible improvement

-Plan your entry and/or expansion activities involving the Indian pharmaceutical market by understanding the market dynamics and identifying possible partners and/or acquisition targets

-Analyze and track the strategies that successful pharmaceutical companies in India are using to gain share in the increasingly competitive market

-Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending, asset structure, and efficiency

-Use this information as an independent source for your due diligence and transaction strategy

1 Table of Contents

1 Table of Contents 6

1.1 List of Tables 12

1.2 List of Figures 14

2 Introduction 16

2.1 Report Scope 16

2.2 Upcoming Related Reports 18

2.3 Recently Published Reports 18

2.4 GlobalData’s Benchmarking Methodology 19

3 India’s Pharmaceutical Industry Dynamics 20

3.1 Overview 20

3.2 Intellectual Property Rights in India 20

3.3 Quality Manufacturing Facilities Create an Ideal Environment for Pharmaceuticals to Thrive 22

3.4 Inter-Firm Competition Enables Capabilities Development 24

3.5 Government Policies and Initiatives Drive Demand 24

3.6 Increased ANDA Filings by Indian Drug Companies 25

3.7 Cost Effect of GDUFA on Indian Drug Companies 30

3.8 A Budding Biosimilars Market 31

3.8.1 Gradual Transition from a Semi-Regulated to a Regulated Market 31

3.8.2 Marketed Biosimilars in India 32

4 Company Analysis 34

4.1 Sun Pharmaceuticals: The Benchmark Leader 34

4.1.1 Business Overview 34

4.1.2 SWOT Analysis 35

4.2 Wockhardt 39

4.2.1 Business Overview 39

4.2.2 SWOT Analysis 40

4.3 Cipla 43

4.3.1 Business Overview 43

4.3.2 SWOT Analysis 44

4.4 Ranbaxy 47

4.4.1 Business Overview 47

4.4.2 SWOT Analysis 48

4.5 Lupin Pharmaceuticals 52

4.5.1 Business Overview 52

4.5.2 SWOT Analysis 53

4.6 Zydus Cadila 56

4.6.1 Business Overview 56

4.6.2 SWOT Analysis 57

4.7 Glenmark 60

4.7.1 Business Overview 60

4.7.2 SWOT Analysis 61

4.8 Torrent Pharmaceuticals 65

4.8.1 Business Overview 65

4.8.2 SWOT Analysis 66

4.9 Dr. Reddy’s 70

4.9.1 Business Overview 70

4.9.2 SWOT Analysis 71

4.10 Aurobindo Pharmaceuticals 75

4.10.1 Business Overview 75

4.10.2 SWOT Analysis 76

5 GlobalData’s Benchmark Rankings 78

5.1 Sun Pharmaceuticals: India’s Leading Pharmaceutical Company 78

6 Financial Management 80

6.1 Competitive Framework 80

6.2 Overview 80

6.3 Financial Management: Heat Map 82

6.4 Financial Metrics 83

6.4.1 Revenue Leaders 83

6.4.2 Revenue Laggards 85

6.4.3 Revenue Growth Leaders 86

6.4.4 Revenue Growth Laggards 88

6.4.5 Operating Income Leaders 90

6.4.6 Operating Income Laggards 91

6.4.7 Operating Income YTY Growth Leaders 93

6.4.8 Operating Income YTY Growth Laggards 94

6.4.9 Operating Margin Leaders 95

6.4.10 Operating Margin Laggards 97

7 Expense Management 99

7.1 Competitive Framework 99

7.2 Overview 100

7.3 Expense Management: Heat Map 103

7.4 Expense Metrics 104

7.4.1 SG&A Spending Leaders 104

7.4.2 SG&A Spending Laggards 105

7.4.3 SG&A Expenditures as a Percentage of Revenue Leaders 106

7.4.4 SG&A Expenditures as a Percentage of Revenue Laggards 108

7.4.5 SG&A Spending YTY Change Leaders 110

7.4.6 SG&A YTY Spending Change Laggards 111

7.4.7 Operating Expenses as a Percentage of Revenue Leaders 113

7.4.8 Operating Expenses Laggards 114

8 Capital Management 116

8.1 Competitive Framework 116

8.2 Overview 116

8.3 Competitive Framework: Heat Map 118

8.4 Capital Management Metrics 119

8.4.1 Debt Ratio Leaders 119

8.4.2 Debt Ratio Laggards 120

8.4.3 Cash Ratio Leaders 121

8.4.4 Cash Ratio Laggards 124

8.4.5 Quick Ratio Leaders 125

8.4.6 Quick Ratio Laggards 126

8.4.7 ROI Leaders 127

8.4.8 ROI Laggards 128

9 Resource Management 130

9.1 Competitive Framework 130

9.2 Overview 130

9.3 Resource Management: Heat Map 133

9.4 Financial Metrics 134

9.4.1 Revenue per Employee Leaders 134

9.4.2 Revenue per Employee Laggards 135

9.4.3 Expenditure per Employee Leaders 137

9.4.4 Expenditure per Employee Laggards 138

10 Geographical Segmentation 140

10.1 India 140

10.2 Europe, Middle East, and Africa 142

10.3 North America 144

10.4 Rest of World 146

11 Strategic Outlook 147

11.1 Current Growth in the Indian Pharmaceutical Industry Expected to Continue 147

11.2 Increased Focus on R&D 148

11.3 Government’s Pricing Revision Will Further Reduce Margins 148

11.4 Stiff Competition from Multinationals May Stymie Development of Smaller Domestic Players 149

11.5 Growing Pressures on Indian Patent Laws Could Challenge Domestic Companies 150

12 Appendix 151

12.1 Bibliography 151

12.2 Abbreviations 153

12.3 Research Methodology 157

12.3.1 Coverage 157

12.3.2 Secondary Research 158

12.3.3 Expert Panel Validation 158

12.4 About the Authors 159

12.4.1 Analyst 159

12.4.2 Director of Healthcare Industry Dynamics 159

12.4.3 Global Head of Healthcare Research and Consulting 160

12.5 About the Industry Dynamics Team 160

12.6 About GlobalData 160

12.7 Disclosure Information 161

12.8 Disclaimer 161

List of Tables

Table 1: First-Time Generic Drug Approvals, 2012 – Part 1 26

Table 2: First-Time Generic Drug Approvals, 2012 – Part 2 27

Table 3: First-Time Generic Drug Approvals, 2012 – Part 3 28

Table 4: First-Time Generic Drug Approvals, 2012 – Part 4 29

Table 5: Biosimilars Currently Marketed in India 33

Table 6: Wockhardt’s Product Pipeline 41

Table 7: Lupin’s Product Pipeline 54

Table 8: Glenmark: Novel Drugs Pipeline 63

Table 9: Torrent Pharmaceuticals’ Current Discovery Portfolio 66

Table 10: Dr. Reddy’s Currently Marketed Biosimilars 73

Table 11: GlobalData’s Benchmark Rankings, Top 10 Pharmaceutical Companies in India, 2012 79

Table 12: Top 10 Indian Pharmaceutical Companies’ FM Composite Scores and Overall FM Scores, 2012 82

Table 13: Revenue-Leading Companies’ FM Composite Scores and Overall FM Scores, 2012 83

Table 14: Top Three Revenue Laggards in 2012 85

Table 15: Top Three Revenue Growth Leaders in 2012 86

Table 16: Top Three Revenue Growth Laggards in 2012 89

Table 17: Top Three Operating Income Leaders in 2012 90

Table 18: Top Three Operating Income Laggards in 2012 91

Table 19: Top Three YTY Operating Income Growth Leaders in 2012 93

Table 20: Top Three YTY Operating Income Growth Laggards in 2012 94

Table 21: Top Three Operating Margin Leaders in 2012 95

Table 22: Top Three Operating Margin Laggards in 2012 97

Table 23: Top 10 Indian Pharmaceutical Companies’ Composite and Overall EM Scores, 2012 103

Table 24: Top SG&A Spending Leaders in 2012 104

Table 25: Top SG&A Spending Laggards in 2012 105

Table 26: Top SG&A Spending as a Percentage of Revenue Leaders, 2012 107

Table 27: Top SG&A Spending as a Percentage of Revenue Laggards, 2012 108

Table 28: Top SG&A Spending YTY Change Leaders 110

Table 29: Top SG&A Spending YTY Change Leaders 111

Table 30: Top Operating Expenses as a Percentage of Revenue Leaders 113

Table 31: Top Operating Expenses Laggards as a Percentage of Revenue 114

Table 32: Top 10 Indian Pharmaceutical Companies’ Composite and Overall CM Scores, 2012 118

Table 33: Top Debt-to-Assets Leaders in 2012 119

Table 34: Debt-to-Assets Laggards in 2012 120

Table 35: Cash Ratio Leaders in 2012 122

Table 36: Cash Ratio Laggards in 2012 124

Table 37: Quick Ratio Leaders in 2012 125

Table 38: Quick Ratio Laggards in 2012 126

Table 39: ROI Leaders in 2012 127

Table 40: ROI Laggards in 2012 128

Table 41: Top 10 Indian Pharmaceutical Companies’ Composite and Overall RM Scores, 2012 133

Table 42: Top Three Revenue per Employee Leaders in 2012 134

Table 43: Top Three Revenue per Employee Laggards in 2012 135

Table 44: Top Three Expenditure per Employee Leaders in 2012 137

Table 45: Top Three Expenditure per Revenue Laggards in 2012 138

List of Figures

Figure 1: Value of Pharmaceutical Exports from India, 2002–2012 23

Figure 2: Sun Pharmaceuticals: SWOT Analysis 35

Figure 3: Wockhardt: SWOT Analysis 40

Figure 4: Cipla: SWOT Analysis 44

Figure 5: Ranbaxy: SWOT Analysis 48

Figure 6: Lupin Pharmaceuticals: SWOT Analysis 53

Figure 7: Zydus Cadila: SWOT Analysis 57

Figure 8: Glenmark: SWOT Analysis 61

Figure 9: Torrent Pharma: SWOT Analysis 66

Figure 10: Dr. Reddy’s: SWOT Analysis 71

Figure 11: Aurobindo Pharmaceuticals: SWOT Analysis 76

Figure 12: Competitive Assessment of the Top 10 Pharmaceutical Companies in India, 2012 81

Figure 13: Leading Pharmaceutical Companies in India by Revenue in 2011 and 2012 86

Figure 14: Leading Pharmaceutical Companies in India by YTY Revenue Growth in 2012 89

Figure 15: Leading Pharmaceutical Companies in India by Operating Income ($ m), 2011 and 2012 92

Figure 16: Leading Pharmaceutical Companies in India by YTY Operating Income Growth 95

Figure 17: Leading Pharmaceutical Companies in India by Operating Margin in 2011 and 2012 98

Figure 18: Competitive Landscape of the Top 10 Pharmaceutical Companies in India in 2012 – SG&A Expenses as a Percentage of Revenue vs. Operating Expenses as a Percentage of Revenue 101

Figure 19: Leading Pharmaceutical Companies in India by SG&A Spending as a Percentage of Revenue, 2011 and 2012 102

Figure 20: Leading Pharmaceutical Companies in India by SG&A Spending, 2011 and 2012 106

Figure 21: Leading Pharmaceutical Companies in India by SG&A Spending as a Percentage of Revenue, 2012 109

Figure 22: Leading Pharmaceutical Companies in India by SG&A Expenditures YTY Change, 2012 112

Figure 23: Leading Pharmaceutical Companies in India by Operating Expenses as a Percentage of Revenue, 2011 and 2012 115

Figure 24: Competitive Landscape of the Top 10 Players in the Indian Pharmaceutical Industry — Debt Ratio vs. Cash Ratio, 2012 117

Figure 25: Leading Pharmaceutical Companies in India by Debt Ratio, 2011 and 2012 121

Figure 26: Leading Pharmaceutical Companies in India by Cash Ratio, 2011 and 2012 124

Figure 27: Leading Pharmaceutical Companies in India by Quick Ratio, 2011 and 2012 127

Figure 28: Leading Pharmaceutical Companies in India by ROI, 2011 and 2012 129

Figure 29: Global Headcount of the Top 10 Players in the Indian Pharmaceutical Industry 131

Figure 30: Competitive Landscape of the Top 10 Players in the Indian Pharmaceutical Industry 132

Figure 31: Leading Pharmaceutical Companies in India by Revenue per Employee, 2011 and 2012 136

Figure 32: Leading Pharmaceutical Companies in India by Expenditure per Employee, 2012 139

Figure 33: Forecast Growth in the Indian Pharmaceutical Market, 2013–2020 ($ bn) 140

Figure 34: Competitive Landscape of the Top 10 Domestic Pharmaceutical Companies in India, 2012 141

Figure 35: Competitive Landscape of the Leading India-based Pharmaceutical Companies in the EMEA Region, 2012 144

Figure 36: Competitive Landscape of the Leading Indian Pharmaceutical Companies in North America, 2012 145

Figure 37: Competitive Landscape of the Leading Indian Pharmaceutical Companies in the ROW, 2012 146

Figure 38: Forecast Growth in the Indian Pharmaceutical Market, 2013–2020 ($ bn) 147

Companies Mentioned:

Sun Pharmaceuticals

Wockhardt

Cipla

Ranbaxy

Lupin Pharmaceuticals

Zydus Cadila

Glenmark

Torrent Pharmaceuticals

Dr. Reddy’s

Aurobindo Pharmaceuticals

Read the full report:

PharmaLeaders: Top 10 Pharmaceutical Companies in India Benchmark Report – Competitive Analysis of the Leading Players in 2013

http://www.reportbuyer.com/pharma_healthcare/general_industry/pharmaleaders_top_10_pharmaceutical_companies_india_benchmark_report_competitive_analysis_leading_players_2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com







Leave a Comment

Your email address will not be published. Required fields are marked *